Trial of solanezumab in preclinical Alzheimer's disease

Cited by (430)

Items 101–200 of 430

1. Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
   Alexandra Wicker, Jahnavi Shriram, Boris Decourt, Marwan Noel Sabbagh · 2024 · Neurology and Therapy
2. Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer's disease
   Bruna Bellaver, Guilherme Povala, Pâmela C.L. Ferreira, Guilherme Bauer‐Negrini, Firoza Zubeida Lussier, Douglas Teixeira Leffa, João Pedro Ferrari‐Souza, Matheus Scarpatto Rodrigues, Lívia Amaral, Markley S. Oliveira et al. · 2025 · Alzheimer s & Dementia
3. Effects of exercise versus usual care on older adults with amnestic mild cognitive impairment: EXERT versus ADNI
   Aladdin H. Shadyab, Vahan Aslanyan, Diane M. Jacobs, David P. Salmon, Rosemary H. Morrison, Jeffrey A. Katula, Shelia Jin, Ronald G. Thomas, Andrea Z. LaCroix, Judy Pa et al. · 2025 · Alzheimer s & Dementia
4. Elecsys pTau217 plasma immunoassay detection of amyloid pathology in clinical cohorts
   Derrek P. Hibar, Alina Bauer, Christina Rabe, Niels Borlinghaus, Alexander Jethwa, Gwendlyn Kollmorgen, Annunziata Di Domenico, Henrik Zetterberg, Kaj Blennow, Colin Louis Masters et al. · 2026 · Alzheimer s & Dementia
5. Sex Differences in P-Tau217, Tau Aggregation, and Cognitive Decline
   Gillian Coughlan, Valentin Ourry, Diana L Townsend, Hannah M Klinger, Jane A. Brown, Madison Cuppels, Tobey J. Betthauser, Rebecca E. Langhough, Karly Alex Cody, Mabel Seto et al. · 2026 · JAMA Neurology
6. Florbetaben amyloid PET acquisition time: Influence on Centiloids and interpretation
   Emily Johns, Hillary A. Vossler, Christina B. Young, Mackenzie L. Carlson, Joseph R. Winer, Kyan Younes, Jennifer Park, Julia E Rathmann-Bloch, Viktorija Smith, Theresa M. Harrison et al. · 2024 · Alzheimer s & Dementia
7. Identification of Blood Biomarkers Related to Energy Metabolism and Construction of Diagnostic Prediction Model Based on Three Independent Alzheimer’s Disease Cohorts
   Hongqi Wang, Jilai Li, Wen‐Jun Tu, Zhi­qun Wang, Yiming Zhang, Lirong Chang, Yan Wu, Xia Zhang · 2024 · Journal of Alzheimer s Disease
8. Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice
   Clifford R. Jack, Ana Graf, Samantha C. Burnham, Erin Gautier Doty, Hans J. Moebius, Philip H. Montenigro, Eric Siemers, Kaycee M. Sink, Leslie M. J. Shaw, Charlotte Thim Hansen et al. · 2024 · Alzheimer s & Dementia Translational Research & Clinical Interventions
9. Clinical Importance of Amyloid Beta Implication in the Detection and Treatment of Alzheimer’s Disease
   Justyna Pokrzyk, Agnieszka Kulczyńska‐Przybik, Ewa Monika Guzik-Makaruk, Izabela Winkel, Barbara Mroczko · 2025 · International Journal of Molecular Sciences
10. Treatments for AD: towards the right target at the right time
    Wiesje M. van der Flier, Betty Marije Tijms · 2023 · Nature Reviews Neurology
11. Targeting Inflammation in Alzheimer’s Disease: Insights Into Pathophysiology and Therapeutic Avenues-A Comprehensive Review
    Vasileios Topalis, Charalampos Voros, Mairi Ziaka · 2025 · Journal of Geriatric Psychiatry and Neurology
12. More failure with solanezumab – this time in preclinical Alzheimer’s disease
    Sheila Anne Doggrell · 2024 · Expert Opinion on Biological Therapy
13. Characterizing Clinical Progression in Cognitively Unimpaired Older Individuals with Brain Amyloid: Results from the A4 Study
    Dorene M. Rentz, P.B. Rosenberg, Reisa Anne Sperling, Michael Donohue, Rema Raman, Aiyi Liu, Paul S. S Aisen · 2024 · The Journal of Prevention of Alzheimer s Disease
14. Greater White Matter Hyperintensity Volume Is Associated with the Number of Microhemorrhages in Preclinical Alzheimer's Disease
    Zahra Shirzadi, Aaron P. Schultz, Michael J Properzi, R. Yaari, W-Y W Yau, Adam M. Brickman, Michael S. Rafii, Michael Donohue, Karin B. Ernstrom, Shuaiwen Wang et al. · 2024 · The Journal of Prevention of Alzheimer s Disease
15. Community recruitment of underrepresented populations to the AHEAD 3‐45 preclinical AD trial using novel partnerships with nursing and community‐based organizations: Lessons and outcomes
    Christian R. Salazar, Melanie B Tallakson, Maria G. Corona, Edwin Duran, Eunji Russ, Dan K. Hoang, Romina A. Romero, David L. Sultzer, Joshua D. Grill, Hye‐Won Shin · 2024 · Alzheimer s & Dementia
16. Targeting Metals in Alzheimer’s Disease: An Update
    Bin Du, Kang Chen, Weiwei Wang, Peng Lei · 2024 · Journal of Alzheimer s Disease
17. Evolution of Alzheimer’s Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy
    Emma Ortiz-Islas, Pedro Montes, Citlali Ekaterina Rodríguez-Pérez, Elizabeth Ruiz-Sánchez, Talía Sánchez-Barbosa, Diego Pichardo-Rojas, Cecilia Zavala‐Tecuapetla, Karla Carvajal, Victoria Campos‐Peña · 2025 · Pharmaceutics
18. A computational medicine framework integrating multi-omics, systems biology, and artificial neural networks for Alzheimer's disease therapeutic discovery
    Yisheng Yang, Yizhu Diao, Lulu Jiang, Fanlu Li, Liye Chen, Ming Ni, Zheng Wang, Hai Fang · 2025 · Acta Pharmaceutica Sinica B
19. White matter hyperintensity on MRI and plasma Aβ42/40 ratio additively increase the risk of cognitive impairment in hypertensive adults
    Adam de Havenon, Rebecca F. Gottesman, Jeff D. Willamson, Natalia S. Rost, Richa Sharma, Vivian Li, Lauren Littig, Eric Lee Stulberg, Guido J. Falcone, Shyam Prabhakaran et al. · 2024 · Alzheimer s & Dementia
20. Detecting early cognitive deficits in preclinical Alzheimer’s disease using a remote digital multi-day learning paradigm
    Roos J. Jutten, Daniel Soberanes, Cassidy P. Molinare, Stephanie Hsieh, Michelle E. Farrell, Aaron P. Schultz, Dorene M. Rentz, Gad A. Marshall, Keith A. Johnson, Reisa Anne Sperling et al. · 2025 · npj Digital Medicine
21. BOLD amplitude correlates of preclinical Alzheimer’s disease
    Stanislau Hrybouski, Sandhitsu R. Das, Long Xie, Christopher Brown, Melissa Flamporis, Jacqueline Lane, Ilya M. Nasrallah, John A. Detre, Paul A. Yushkevich, David A. Wolk · 2025 · Neurobiology of Aging
22. Monoclonal antibodies for treating early Alzheimer disease—a commentary on recent ‘positive’ trials
    Ian A Scott · 2024 · Age and Ageing
23. Pulse pressure as a predictor of Alzheimer’s disease biomarkers and cognitive decline: The moderating role of APOE ε4
    Joon Hyung Jung, Nayeong Kong, Seung‐Hoon Lee · 2025 · The Journal of Prevention of Alzheimer s Disease
24. Prognostic value of plasma glial fibrillary acidic protein in cognitively unimpaired older adults: Results from the A4 study
    Elham Ghanbarian, Tianchen Qian, Babak Khorsand, Lukai Zheng, S. Ahmad Sajjadi, Joshua D. Grill, Laura A. Rabin, Richard B. Lipton, Reisa Anne Sperling, Ali Ezzati · 2025 · Alzheimer s & Dementia
25. Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer’s clinical trial participants
    Clarissa D. Morales, Dejania Cotton‐Samuel, Patrick J. Lao, Julia F. Chang, Jeffrey D. Pyne, Mohamad J. Alshikho, Rafael Vignoli Lippert, Kelsang C. Bista, Christiane Hale, Natalie C. Edwards et al. · 2024 · Alzheimer s Research & Therapy
26. Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data
    Gustavo Adolfo Jimenez‐Maggiora, A.P. Schulz, Michael Donohue, H. Qiu, S.N. Jaiswal, Olusegun Adegoke, R. Gallardo, O Baryshnikava, Robert A. Rissman, Sara Abdel‐Latif et al. · 2024 · The Journal of Prevention of Alzheimer s Disease
27. A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer's Disease
    Tianle Chen, R. Matthew Hutchison, C Rubel, J. Murphy, Jin Xie, Philip H. Montenigro, Weyland Cheng, Kyle B. Fraser, Gersham W. Dent, S Hendrix et al. · 2024 · The Journal of Prevention of Alzheimer s Disease
28. MAD—microbial (origin of) Alzheimer’s disease hypothesis: from infection and the antimicrobial response to disruption of key copper-based systems
    Jin-Hong Min, Heela Sarlus, Robert Adam Harris · 2024 · Frontiers in Neuroscience
29. Advancing pharmacometrics in Africa—Transition from capacity development toward job creation
    Goonaseelan Colin Pillai, Samer Mouksassi, Innocent Gerald Asiimwe, Craig R. Rayner, Steven E. Kern, Phumla Sinxadi, Paolo Denti, Eric H. Decloedt, Catriona John Waitt, Bernhards Ragama Ogutu et al. · 2024 · CPT Pharmacometrics & Systems Pharmacology
30. Association of the digital clock drawing test with amyloid and tau PET biomarkers in low age risk adults
    Huitong Ding, Chenglin Lyu, Cody Karjadi, Preeti Sunderaraman, Christina B. Young, Elizabeth C. Mormino, Spencer Low, Sherral Devine, Katherine A. Gifford, Rhoda Au et al. · 2025 · Scientific Reports
31. Plasma p-tau217 predicting brain-wide tau accumulation in preclinical AD
    Hasom Moon, Xi Chen · 2025 · The Journal of Prevention of Alzheimer s Disease
32. Tailored antisense oligonucleotides for ultrarare CNS diseases: An experience-based best practice framework for individual patient evaluation
    Rebecca Schüle, Holm Graeßner, Annemieke M Aartsma-Rus, Willeke van Roon‐Mom, Matthis Synofzik · 2025 · Molecular Therapy — Nucleic Acids
33. The structural foundations of anti-amyloid-β immunotherapies: Unravelling antibody-antigen interactions in Alzheimer's disease treatment
    Luke A. Miles, Colin Louis Masters · 2025 · Journal of Alzheimer s Disease
34. Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia‐specific perspectives
    Takeshi Iwatsubo, Reisa Anne Sperling, Alicia Algeciras‐Schimnich, Hidenori Arai, Anna M. Barron, Tammie L.S. Benzinger, María C. Carrillo, Christopher Chen, Seong Hye Choi, Igor Camargo Fontana et al. · 2025 · Alzheimer s & Dementia
35. Review of anti-amyloid-beta (Aβ) monoclonal antibodies for the treatment of Alzheimer’s disease
    Emily Francis, Samantha Paylor, Cornelis Van, Bindu Mathews, Millad J. Sobhanian, Daniel Z. Mansour, George Hennawi, Nicole Brandt · 2025 · Expert Review of Clinical Pharmacology
36. Dementia research in 2023: the year of anti-amyloid immunotherapy
    Julien Delrieu, Sandrine Andrieu, Bruno J. Vellas · 2023 · The Lancet Neurology
37. Prediction of future cognitive decline among cognitively unimpaired individuals using measures of soluble phosphorylated tau or tau tangle pathology
    Rik Ossenkoppele, Gemma Salvadó, Shorena Janelidze, Alexa Pichet Binette, Divya Bali, Linda Karlsson, Sebastian Palmqvist, Niklas Mattsson, Erik Stomrud, Joseph Therriault et al. · 2024 · medRxiv
38. Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer's Disease: Secondary Analyses from the A4 Study
    Kathryn V. Papp, Paul T. Maruff, Dorene M. Rentz, Michael Donohue, Andy Liu, Paul S. S Aisen, Reisa Anne Sperling · 2024 · The Journal of Prevention of Alzheimer s Disease
39. Therapeutic agents for Alzheimer’s disease: a critical appraisal
    Marta Weinstock · 2024 · Frontiers in Aging Neuroscience
40. A Machine Learning Approach to Predict Cognitive Decline in Alzheimer Disease Clinical Trials
    Bhargav Teja Nallapu, Kellen K. Petersen, Tianchen Qian, İdris Demirsoy, Elham Ghanbarian, Christos A. Davatzikos, Richard B. Lipton, Ali Ezzati, Alzheimer’s Disease Neuroimaging Initiative, Michael Walter Weiner et al. · 2025 · Neurology
41. Higher Educational Attainment and Accelerated Tau Accumulation in Alzheimer Disease
    Yue Qin Cai, Lili Fang, Jie Yang, Xin Yu Zhou, Lin Liu, Anqi Li, Pan Sun, Guoyu Lan, Zhengbo He, Yalin Zhu et al. · 2025 · JAMA Neurology
42. Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease
    Viswanath Devanarayan, Michael Donohue, Reisa Anne Sperling, Keith A. Johnson, Yuanqing Ye, Arnaud Charil, T. Doherty, Lü Tian, Rema Raman, Paul S. S. Aisen et al. · 2025 · Alzheimer s & Dementia
43. Alzheimer's disease: from molecular pathways to therapies
    Jing-Qiu Feng, Ling-Ling Yang, Luo Ya-xi, Xiu‐Qing Yao · 2026 · Molecular Biomedicine
44. Mitophagy in Alzheimer’s Disease: A Bibliometric Analysis from 2007 to 2022
    Hongqi Wang, Xiaodong Yan, Yiming Zhang, Peifu Wang, Jilai Li, Xia Zhang · 2024 · Journal of Alzheimer s Disease Reports
45. Alzheimer's Disease Neuroimaging Initiative: Two decades of pioneering Alzheimer's disease research and future directions
    Ozioma C. Okonkwo, Mónica Rivera Mindt, Michael Walter Weiner, Alzheimer’s Disease Neuroimaging Initiative · 2025 · Alzheimer s & Dementia
46. Prospective Multicenter Evaluation of the MDS “Suggestive of PSP ” Diagnostic Criteria
    Andrea Quattrone, Nicolai Franzmeier, Johannes Levin, Gabor C. Petzold, Annika E. Spottke, Frederic Brosseron, Björn H. Falkenburger, Johannes Prudlo, Thomas Gasser, The DESCRIBE‐PSP Group, The ProPSP Group et al. · 2025 · Movement Disorders
47. Alpha-synuclein in Parkinson's disease: Embracing debate, exercising skepticism
    Alberto Javier Espay, Andrew John Lees, Francisco Cardoso, Steven J. Frucht, Daniel Erskine, Andrea Sturchio, Alberto Imarisio, Christian Hoffmann, Kora T Montemagno, Samuel Naudi-Fabra et al. · 2025 · Parkinsonism & Related Disorders
48. Crossing Barriers: Advancements in Macromolecular Therapeutics for Neurodegenerative Diseases and Strategies to Overcome the Blood–Brain Barrier
    Bekas Alo, Christina Lamers · 2025 · ACS Pharmacology & Translational Science
49. Restoring amyloid-β42 and γ-secretase function in Alzheimer’s disease
    Alberto Javier Espay, Kariem Ezzat, Kasper P. Kepp, Timothy P Daly, Nikolaos K. R K Robakis, Laurent Meijer, Bruno Pietro Imbimbo · 2025 · Brain
50. Targeting the awry Aβ pathway in Alzheimer’s disease: hype and hurdles
    Hayder Mutter Al-Kuraishy, Ghassan Mohammad Sulaiman, Ali Ismail Al-Gareeb, Hamdoon Abdelhamid Mohammed, Ali K. Albuhadily, Mosleh Mohammad Abomughaid · 2025 · Inflammopharmacology
51. Defining patient‐centered amyloid PET thresholds for the onset of tauopathy in Alzheimer's disease
    Zeyu Zhu, Anna Steward, Amir Dehsarvi, Sebastian Niclas Roemer, Anna Dewenter, Davina Biel, Fabian Hirsch, Lukas K. Frontzkowski, Julia Pescoller, Madleen Klonowski et al. · 2026 · Alzheimer s & Dementia
52. A high-throughput, quantitative platform using 2D dissociated human cerebral organoids to model neuroinflammation in Alzheimer’s disease
    Meagan N. Olson, Pepper Dawes, Liam F. Murray, Nathaniel Barton, Jonathan Sundstrom, Adrian R. Orszulak, Samantha M. Chigas, Khanh Tran, Aimee J. Aylward, Michele F. Caliandro et al. · 2026 · npj Dementia
53. Creating an Unprotected Class: Addressing Legal Risks in the Era of Biologically-Defined Alzheimer’s Disease
    Neil Vaishnav, Rosa Gonzalez, Krystal L. Karunungan, Ana M. Tyler, William Zheng, Jalayne J. Arias · 2024 · Journal of Alzheimer s Disease
54. Pre-Randomization Predictors of Study Discontinuation in a Preclinical Alzheimer's Disease Randomized Controlled Trial
    Rema Raman, Kedir Hussen, Michael Donohue, Karin B. Ernstrom, Karen Chilcott Holdridge, Oliver Langford, Doris P. Molina‐Henry, Aimee L. Pierce, John Randall Sims, Amanda Elizabeth Smith et al. · 2024 · The Journal of Prevention of Alzheimer s Disease
55. Use of Robust Norming to Create a Sensitive Cognitive Summary Score in De Novo Parkinson's Disease: An Illustrative Example
    Daniel A. Weintraub, Michael C. Brumm, Ryan Kurth, Michele K. York, the Parkinson's Progression Markers Initiative · 2025 · Movement Disorders
56. Independent effects of white matter lesion volume and APOE ɛ4 on ARIA‐H in A4 Study
    Zahra Shirzadi, Aaron P. Schultz, Nazila Loghmani, Hyun‐Sik Yang, Jeremy N. Ford, Roy Yaari, Michael J Properzi, Wai‐Ying Wendy Yau, Lei Liu, Michael S. Rafii et al. · 2025 · Alzheimer s & Dementia
57. Longitudinal Associations of Multimodal Core 1 Alzheimer Disease Biomarkers With Cognition in Aging and Preclinical Alzheimer Disease
    David López‐Martos, Marc Suárez‐Calvet, Marta Milà‐Alomà, Juan Domingo Gispert, Gemma Salvadó, Anna Brugulat‐Serrat, Mahnaz Shekari, Carolina Minguillón, Henrik Zetterberg, Kaj Blennow et al. · 2025 · Neurology
58. Alzheimer’s Disease Diagnosis and Management in the Age of Amyloid Monoclonal Antibodies
    Chadwick M. Hales · 2024 · Medical Clinics of North America
59. A data-driven framework for biomarker discovery applied to optimizing modern clinical and preclinical trials on Alzheimer’s disease
    Isaac Llorente Saguer, Neil P. Oxtoby · 2024 · Brain Communications
60. INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease
    Eric Siemers, Todd Feaster, Gopalan Sethuraman, Karen L. Sundell, Vladimir Skljarevski, Erika N. Cline, Hao Zhang, Jasna Jerecı̀ć, Lawrence S. Honig, Stephen Salloway et al. · 2025 · The Journal of Prevention of Alzheimer s Disease
61. Uncertainties in anti-amyloid monoclonal antibody therapy for Alzheimer’s disease: the challenges ahead
    Madia Lozupone, Vittorio Dibello, Emanuela Resta, Rodolfo Sardone, Fabio Castellana, Roberta Zupo, Luisa Lampignano, Ilaria Bortone, Anita Mollica, Giuseppe Berardino et al. · 2025 · Expert Review of Neurotherapeutics
62. A new, all‐encompassing aetiology of type 1 diabetes
    Piet C. de Groen · 2023 · Immunology
63. Ion transporter cascade, reactive astrogliosis and cerebrovascular diseases
    Md Shamim Rahman, Rabia Islam, Mohammad Iqbal H. Bhuiyan · 2024 · Frontiers in Pharmacology
64. Lecanemab for Alzheimer Disease
    Sarah E. Nelson, Oscar L. López · 2024 · Neurology
65. Plasma p-tau217 predicts cognitive impairments up to ten years before onset in normal older adults
    Yara Yakoub, Fernando González‐Ortiz, Nicholas James Ashton, Christine Déry, Cherie Strikwerda‐Brown, Frédéric St‐Onge, Valentin Ourry, Michael Schöll, Maiya Rachel Geddes, Simon Ducharme et al. · 2024 · medRxiv
66. What the gantenerumab trials teach us about Alzheimer's treatment
    Schneider, Lon S. · 2023 · New England Journal of Medicine
67. Combination therapy targeting Alzheimer's disease risk factors is associated with a significant delay in Alzheimer's disease–related cognitive decline
    Yuan Shang, Georgina Torrandell‐Haro, Francesca Vitali, Roberta Díaz Brinton, The Alzheimer's Disease Neuroimaging Initiative (ADNI) · 2025 · Alzheimer s & Dementia Translational Research & Clinical Interventions
68. Changes in Daily Functioning in Association With Tau and Amyloid Among Unimpaired Older Adults With and Without Elevated Amyloid
    Mark A. Dubbelman, Andy Liu, Michael Donohue, Oliver Langford, Rema Raman, Dorene M. Rentz, Rebecca England Amariglio, Reisa Anne Sperling, Paul S. S Aisen, Gad A. Marshall et al. · 2025 · Neurology
69. Next-generation neurotherapeutics: mechanistic insights on monoclonal antibodies in Alzheimer’s disease
    Akhil Sharma, Thakur Gurjeet Singh · 2025 · Brain Research
70. Advancement of disease-modifying therapy of Alzheimer’s disease: from the perspective of new revised criteria for diagnosis and staging of Alzheimer’s disease
    Jie Wu, Chaofan Geng, Liyang Liu, Yi Tang · 2025 · Medicine Plus
71. Digital memory assessments and plasma pTau217 enable efficient preclinical Alzheimer’s trials
    Casey R. Vanderlip, Daniel L. Gillen, Joshua D. Grill, Craig E.L. Stark · 2026 · The Journal of Prevention of Alzheimer s Disease
72. Plasma p-tau217, p-tau181, and Aβ42 predict amyloid PET positivity in cognitively unimpaired adults
    Rui Bao, Wanying Shi, Hongbo Bao, Tonghua Zhang, Xueying Li, Wencai Ding, for the A4 and LEARN Study; The Health and Aging Brain Study (HABS-HD) Study Team, Sid E. O’Bryant, Kristine S. Yaffe, Arthur W. Toga et al. · 2026 · Alzheimer s Research & Therapy
73. Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment
    Rachel F. Buckley, Diana L Townsend, Colin Birkenbihl, Madison Cuppels, Gillian Coughlan, Mabel T. Seto, Jane A. Brown, Michael J Properzi, Merle C. Hönig, Annie Li et al. · 2026 · JAMA
74. Genes related to neurotransmitter receptors as potential biomarkers for Alzheimer's disease
    Wei Chen, Taoyuan Zhang, Hui Zhang · 2024 · Neuroscience Letters
75. Biomarkers and Target-Specific Small-Molecule Drugs in Alzheimer’s Diagnostic and Therapeutic Research: From Amyloidosis to Tauopathy
    Sheng Li, Rajiv Bhalla · 2024 · Neurochemical Research
76. Identifying longitudinal cognitive resilience from cross-sectional amyloid, tau, and neurodegeneration
    Rory Thomas Boyle, Diana L Townsend, Hannah M Klinger, Catherine E Scanlon, Ziwen Yuan, Gillian Coughlan, Mabel Seto, Zahra Shirzadi, Wai‐Ying Wendy Yau, Roos J. Jutten et al. · 2024 · Alzheimer s Research & Therapy
77. Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review.
    Waguih William IsHak, Ashley Meyer, Luiza Freire, Jayant Totlani, Nathalie Murphy, Sabrina Renteria, Mohamed Salem, Tiffany Chang, Rasha Abdelsalam, Rida Khan et al. · 2024 · PubMed Central
78. Lower locus coeruleus integrity is associated with diminished practice effects in clinically unimpaired older individuals
    Lindsay F. Smegal, Marion Baillet, Christoph Schneider, Roos J. Jutten, Rory Thomas Boyle, Dorene M. Rentz, Keith A. Johnson, Reisa Anne Sperling, Kathryn V. Papp, Heidi I.L. Jacobs · 2025 · Neurobiology of Aging
79. The Efficacy and Safety of Amyloid Beta‐Directed Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta‐Analysis of Phase III Randomized Controlled Trials
    Yun Wei, Hualing Li · 2025 · Human Psychopharmacology Clinical and Experimental
80. ApoE4 lowers the ptau217 threshold for tau aggregation and spread in an allele dose-dependent manner
    Anna Steward, Anna Dewenter, Fabian Hirsch, Sebastian Niclas Roemer, Zeyu Zhu, Amir Dehsarvi, Davina Biel, Madleen Klonowski, Lukas K. Frontzkowski, Carla Palleis et al. · 2025 · Brain
81. Elevated temporal tau PET predicts faster cognitive decline in women than men: A meta‐analysis
    Annie Li, Hannah M Klinger, Mabel Seto, Colin J. Birkenbihl, Michael J Properzi, Michelle E. Farrell, Emma G. Thibault, Aaron P. Schultz, Diana L Townsend, Madison Cuppels et al. · 2026 · Alzheimer s & Dementia
82. Multi-modal Neuroimaging Phenotyping of Mnemonic Anosognosia in the Aging Brain
    Elisenda Bueichekú, Ibai Palacio Diez, Geoffroy Pierre Gagliardi, Chan Mi Kim, Kayden J. Mimmack, Jorge Sepulcre, Patrizia Vannini · 2024 · Communications Medicine
83. An efficient ANN SoC for detecting Alzheimer's disease based on recurrent computing
    Zhikang Chen, Yuejun Zhang, Ziyu Zhou, Lixun Wang, Huihong Zhang, Pengjun Wang, Jinyan Xu · 2024 · Computers in Biology and Medicine
84. Cognitive function instrument-based anosognosia to predict amyloid status
    Yuichiro Furuya, Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Kazushi Suzuki, Atsushi Iwata, Takeshi Iwatsubo · 2025 · Journal of Alzheimer s Disease
85. Disclosure of elevated amyloid status is not associated with long‐term suicidality in a preclinical AD trial
    Joshua D. Grill, Rema Raman, Charlene Flournoy, Karin B. Ernstrom, Aimee L. Pierce, Amanda Smith, Paul Rosenberg, Jeffrey Murray Burns, Jason H. Karlawish, Paul S. S Aisen et al. · 2025 · Alzheimer s & Dementia
86. Antiamyloid treatment for dementia: concerns outweigh hopes
    Leon A Flicker · 2025 · Current Opinion in Psychiatry
87. APP β-CTF triggers cell-autonomous synaptic toxicity independent of Aβ
    Mengxun Luo, Jia Zhou, Cailu Sun, Wanjia Chen, Chaoying Fu, Chenfang Si, Yaoyang Zhang, Yang Geng, Yelin Chen · 2024 · eLife
88. The Cognivue Amyloid Risk Measure (CARM): A Novel Method to Predict the Presence of Amyloid with Cognivue Clarity
    James E. Galvin, Michael J. Kleiman, Heather M. Harris, Paul W. Estes · 2025 · Neurology and Therapy
89. The Efficacy of Solanezumab in Patients with Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Clinical Trials
    Mathias S. Renteros-Ramirez, Renzo Barreto-Abanto, Diego C. Huapaya, Mateo Tovar-Cobos, Richard D. Alvarado-Ramos, Oriana Rivera‐Lozada, Joshuan J. Barboza · 2025 · Pharmaceutics
90. Alzheimer's disease Stage 1 and 2: Biology, diagnostics, and treatment
    Suzanne E. Schindler, Oskar Hansson, Alicia Algeciras‐Schimnich, Jalayne J. Arias, Brent W. Beasley, Gill Farrar, Nicole R. Fowler, Sarah M. Hartz, Clifford R. Jack, Linus Jönsson et al. · 2026 · Alzheimer s & Dementia Translational Research & Clinical Interventions
91. Incremental value of plasma biomarkers in predicting clinical decline among cognitively unimpaired older adults: Results from the A4 trial
    Babak Khorsand, Elham Ghanbarian, Laura A. Rabin, S. Ahmad Sajjadi, Ali Ezzati · 2026 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
92. Development and assessment of algorithms for predicting brain amyloid positivity in a population without dementia
    Lisa Le Scouarnec, Vincent Bouteloup, Pieter J. van der Veere, Wiesje M. van der Flier, Charlotte Elisabeth Teunissen, Inge M.W. Verberk, Vincent Planche, Geneviève Chêne, Carole Dufouil · 2024 · Alzheimer s Research & Therapy
93. Favorable long-term cognitive outcomes following recurrent ARIA linked to amyloid-lowering therapies: two cases
    Matteo Zavarella, Giordano Cecchetti, Giulia Rugarli, Alma Ghirelli, Ilaria Bottale, Francesca Orlandi, Edoardo Gioele Spinelli, Roberto Santangelo, Francesca Caso, Sonia Francesca Calloni et al. · 2025 · Journal of Neurology
94. Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's disease
    David M. Cash, Katy E. Morgan, Antoinette O’Connor, Thomas D. Veale, Ian B. Malone, Teresa Poole, Tammie L.S. Benzinger, Brian Andrew Gordon, Laura Ibáñez, Yan Li et al. · 2025 · The Journal of Prevention of Alzheimer s Disease
95. Role of Monoclonal Antibodies in Alzheimer’s Disease: Successes, Failures, and Future Directions
    Arushi Gupta, Sonu Pahal, Vivek Kumar, Amit Chaudhary · 2025 · Neurological Sciences
96. The challenging concept of preclinical Alzheimer's disease
    David Wallon, Antoine Garnier‐Crussard · 2025 · Revue Neurologique
97. Advances in neurological therapies: A review of clinical trials in Alzheimer’s, Parkinson’s, and multiple sclerosis
    Pedro César de Souza, Thaynara Paula Warren Bezerra, Moacyr Jesus Barreto de Melo Rêgo, Michelle Melgarejo da Rosa · 2025 · The American Journal of Medicine
98. Molecular Mechanism of Beta-Amyloid Aggregation Inhibition by KLVFF
    Kevin Cobos-Montes, Sebastián E. Fuentes, Francisca Estuardo, Constanza Cárdenas, Fanny Guzmán, Paula Santana, Javiera Gavilán, Maximiliano Figueroa, Jorge Fuentealba, Verónica A. Jiménez et al. · 2025 · Journal of Chemical Information and Modeling
99. Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial
    Pierre N. Tariot, Francisco Javier Lopera, Silvia Ríos‐Romenets, Kaycee M. Sink, Margarita Giraldo, Natalia Acosta‐Baena, Gustavo Villegas, Alejandro Ceja Espinosa, Marisol Londoño Castaño, C. Gutiérrez Muñoz et al. · 2026 · The Lancet Neurology
100. Body Composition and Alzheimer’s Disease: A Holistic Review
     G. Frank, P. Gualtieri, R. Cianci, Mario Caldarelli, Roselisa Palma, G. D. De Santis, Chiara Porfilio, Francesco Nicoletti, G. Bigioni, L. di Renzo · 2024 · International Journal of Molecular Sciences